Nivolumab injection-induced myasthenia gravis
10.3760/cma.j.issn.1008-5734.2020.02.011
- VernacularTitle:纳武利尤单抗注射液致重症肌无力
- Author:
Man DUAN
1
;
Xinghua LI
;
Xiaoxia TANG
Author Information
1. 武汉科技大学附属孝感医院药学部临床药学室，湖北省孝感市 432000
- Publication Type:Journal Article
- Keywords:
Nivolumab;
Myasthenia gravis;
Dyspnea
- From:
Adverse Drug Reactions Journal
2020;22(2):109-110
- CountryChina
- Language:Chinese
-
Abstract:
A 53-year-old female patient received an IV infusion of nivolumab 140 mg once daily 20 months after the operation of intrahepatic cholangiocarcinomas. The drug was used on the first and 20th days of the treatment. On day 3 of the second injection of the drug, the patient developed weakness in both lower limbs, which was aggravated on day 14, accompanied by symptoms such as blurred vision, ptosis, chest tightness, short of breath, and palpitation. On day 24 of the second injection of the drug, her condition became worse, the patient raved, then developed no response to voice stimuli. The patient′s consciousness recovered after mechanical ventilation with nasotracheal intubation and symptomatic and supportive treatments. The patient was diagnosed as drug-induced myasthenia gravis crisis combined with heart failure and respiratory failure. After 19 days of treatments with hormone and human immune globulin, her ptosis and palpitation were improved. However, her respiratory failure was not improved. She was unable to breathe spontaneously.
